IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

NCT05780307 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor
Non-small Cell Lung Cancer
Small Cell Lung Cancer
Breast Cancer
Squamous Cell Cancer of Head and Neck
Colorectal Cancer

Interventions

DRUG: IMM2520

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Collaborators

[object Object]